N.Y. attorney general investigates insurers' hepatitis C drug coverage

New York Attorney General Eric Schneiderman has issued subpoenas to 16 major commercial health insurers in the state seeking information on how they decide to either authorize or deny coverage for expensive hepatitis C treatments, the Wall Street Journal reports. Schneiderman's office claims that thousands of patients may have been illegally denied coverage for hepatitis C drugs, and it wants to know whether insurers in the state accurately disclosed what they consider medically necessary.

"We feel the subpoena is overly broad, and doesn't take into consideration the impact of the excessive pricing of the drug," a spokeswoman for the New York Health Plan Association tells the WSJ. The New York probe comes in the wake of class-action lawsuits filed against state Medicaid departments challenging decisions to deny coverage for new hepatitis C treatments to patients and prisoners. Article

Free Webinar

Take Control of Your Escalating Claim Costs through a Comprehensive Pre-payment Hospital Bill Review Solution

Today managing high dollar claim spend is more important than ever for Health Plans, TPAs, Employers, and Reinsurers, and can pose significant financial risks. How can these costs be managed without being a constant financial drain on your company resources? Our combination of the right people and the right technology provides an approach that ensures claims are paid right, the first time. Register Now!

Suggested Articles

Learn how health plans can demonstrate agility with analytics to shape benefit plans in a time of healthcare transformation.

HHS Secretary Alex Azar announced the government will distribute 30,000 doses of a new COVID-19 antibody cocktail on Tuesday.

Employers are increasingly integrating their health benefits as a way to achieve cost savings, according to a new report from Anthem.